SPRUCE BIOSCIENCES INC

SPRBNASDAQ

🏆 #2998 by market capEarnings Aug 12 · PostUS Equity

$46.41▲ $0.21 (+0.45%)

🌙 After hours$46.41▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$128M

Small Cap

📈Revenue Growth (YoY)

-100.0%

Declining

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

No chart data available for SPRB.

Trading Snapshot

Day Range: $46.14 – $47.33
52-Week Range: $7.00 – $240.00
Volume: $5.08B
Avg Volume: $5.43B
Shares Outstanding: 2.8M
Next Earnings: Sep 22, 2026

Fundamentals Snapshot

Annual Revenue: $19M
Last Q Revenue: $5M
P/E Ratio: -1.2
P/S Ratio: 0.0x
EPS (TTM): $-27.11
Dividend Yield: 0.00%

Why Investors Own SPRB

✓High-growth profile — revenue up +52.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$19M▲ +49.9% YoY

Gross Margin (TTM)

26.9%▼ −0.5% YoY

Operating Income (TTM)

$4M▲ +49.9% YoY

Free Cash Flow (TTM)

$3M▲ +49.9% YoY

About SPRUCE BIOSCIENCES INC

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

🦦